BioCryst Pharmaceuticals BCRX Business Segments — Interest Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's business segments — interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's business segments — interest expense?
- BioCryst Pharmaceuticals (BCRX) reported business segments — interest expense of $19.78M in Q1 2026.
- How has BioCryst Pharmaceuticals's business segments — interest expense changed year-over-year?
- BioCryst Pharmaceuticals's business segments — interest expense decreased by 15.8% year-over-year, from $23.49M to $19.78M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — interest expense?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's business segments — interest expense has grown at a -7.3% compound annual growth rate (CAGR), from $99.09M to $78.87M.
- What does business segments — interest expense mean?
- Represents the cost of borrowing funds, including interest on debt obligations and amortization of debt issuance costs. High levels of interest expense relative to revenue can indicate significant financial leverage and risk.